Kraft Heinz (NASDAQ:KHC) named Steve Cahillane as its next chief executive officer, tapping the former Kellanova chief to guide the food giant through its planned separation into two independently traded companies.
Corteva (NYSE:CTVA), the agricultural technology giant, and Hexagon Bio, a biotechnology company focused on nature-derived therapeutics, announced a multi-million-dollar joint venture aimed at accelerating the discovery of new crop protection solutions.
Cosette Pharmaceuticals said the U.S. Food and Drug Administration has approved its abbreviated new drug application for the first generic version of CIPRO HC, granting the company 180 days of Competitive Generic Therapy exclusivity and ending a more than 27-year stretch without a generic alternative.
Viewbix (NASDAQ:VBIX) agreed to acquire between 85% and 100% of Quantum X Labs in a share-based transaction that brings the company deeper into AI-quantum computing, adding a portfolio of four technology businesses and a patent claiming significant advances in quantum error correction.
Royalty Pharma (NASDAQ:RPRX) said it has acquired a royalty interest in two of Nuvalent’s lead cancer programs for as much as $315 million, adding long-dated exposure to a pair of next-generation tyrosine kinase inhibitors targeting ALK- and ROS1-altered non-small cell lung cancer.
Palvella Therapeutics (NASDAQ:PVLA) said the U.S. Food and Drug Administration has granted Fast Track Designation to QTORIN 3.9% rapamycin anhydrous gel for treating angiokeratomas, a dermatologic condition with no currently approved therapies.
Flowserve Corp. (NYSE:FLS) said it has acquired Greenray Turbine Solutions, a U.K.-based specialist in aftermarket products and services for industrial gas turbines, in a move that broadens its rotating-equipment capabilities and adds recurring revenue tied to mission-critical infrastructure.
Nektar Therapeutics (NASDAQ:NKTR) reported mixed Phase 2b results for rezpegaldesleukin in severe-to-very-severe alopecia areata, showing meaningful clinical activity but narrowly missing the trial’s primary endpoint in the modified intent-to-treat population.
The Brand House Collective (NASDAQ:TBHC) reported another quarter of pressured results as e-commerce declines and margin compression overshadowed gains in store traffic.
ATS Corporation (NYSE:ATS) named Doug Wright as its next chief executive officer, concluding a broad leadership search as the automation and industrial technology company prepares for its next phase of growth.
